The Pioneer and Leader in Next Generation Antibody Drug Conjugates (ADCs)

Progress, News, and Updates

Read about our latest strides in precision biologics innovation. Stay in the know with our advancements through timely news, presentations, thought-provoking events, and insightful glimpses into the future.

Read here for a description of the expanded genetic code technology featured in Nature.

Latest News

Ambrx to Participate in the Cantor Fitzgerald Global Healthcare Conference

Ambrx to Present Preliminary ARX517 First-in-Human Safety, Efficacy, and Pharmacokinetics Data at ESMO 2023

FDA Grants Fast Track Designation for Ambrx’s ARX517 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Focused Oncology Portfolio

We are advancing enhanced antibody-drug conjugate, immuno-oncology conjugate and bispecific candidates as potential treatments for cancer.

Expanded Genetic Code Technology Platform

We incorporate synthetic amino acids into proteins within living cells. The result? Product candidates designed for highly stable, site-specific conjugation, overcoming the inherent limitations of conventional conjugation approaches.